Aeterna Zentaris Inc. Overview
Pro stress-test →Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing therapeutics and diagnostic tests, with its lead product macimorelin—a ghrelin receptor agonist for diagnosing adult and childhood-onset growth hormone deficiency. Macrilen (macimorelin) is the first and only U.S. FDA and European Commission approved oral test for adult growth hormone deficiency diagnosis, currently marketed in the U.S. through Novo Nordisk with double-digit royalties.
Strategic Profile
Pro stress-test →The company is engaged in developing and commercializing a diverse portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Aeterna is actively pursuing business development opportunities for macimorelin commercialization in Europe and globally, while monetizing other non-strategic assets. Following a 2024 merger with Ceapro, the company now generates revenues from multiple sources including proprietary oat beta glucan and avenanthramides technology.
Competitive Landscape
Pro stress-test →Aeterna's concentrated focus on endocrinology and oncology positions it in a select group; while multiple firms compete in these segments, Aeterna's clinical data and commercialization strategy differentiate it, though it remains smaller than established endocrinology majors like Novo Nordisk and Eli Lilly. Primary competition comes from traditional growth hormone deficiency diagnostics and emerging diagnostic competitors.
Industry Context
Aeterna Zentaris Inc. operates in Specialty Biopharmaceutical / Rare Disease Diagnostics & Therapeutics.
Key facts
Founded: 1990 · Headquarters: Summerville, South Carolina, United States · Employees: 11-50 · Market cap: $17.5M